Welcome to our dedicated page for Oruka Therapeutics news (Ticker: ORKA), a resource for investors and traders seeking the latest updates and insights on Oruka Therapeutics stock.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, and its news flow reflects the progress of a focused dermatology pipeline. Company press releases highlight advances for its lead monoclonal antibodies ORKA-001 and ORKA-002, both engineered to target key immunology pathways in plaque psoriasis and related conditions while enabling infrequent dosing.
News updates frequently cover clinical milestones such as Phase 1 interim data, initiation and enrollment of Phase 2 trials, and detailed designs of the EVERLAST-A and EVERLAST-B studies of ORKA-001 in moderate-to-severe plaque psoriasis. Oruka also reports on the first-in-human trial of ORKA-002, including pharmacokinetic and pharmacodynamic findings that support potential twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa.
In addition to pipeline developments, Oruka’s news includes quarterly financial results, corporate updates, and capital-raising activities, such as a private placement financing described in company communications. Governance and leadership items, including board appointments and executive promotions, are disclosed through both press releases and Form 8-K filings. The company also announces participation in major healthcare and investor conferences, where it presents clinical data and corporate overviews.
Investors and observers following ORKA news can expect coverage of clinical trial data readouts, regulatory milestones such as IND clearance, financing transactions, and changes in leadership or board composition. This page aggregates those updates so readers can monitor how Oruka’s psoriatic disease programs and broader antibody portfolio evolve over time.
Oruka Therapeutics (Nasdaq: ORKA) reported positive interim Phase 1 data for ORKA-002 and trial updates for ORKA-001 on Jan 12, 2026. ORKA-002 showed a 75–80 day half-life, >3x that of bimekizumab, and comparable Cmax, supporting pharmacokinetic modeling for twice-yearly maintenance dosing in plaque psoriasis and quarterly dosing in hidradenitis suppurativa. The Phase 1 (n=24) safety profile was favorable with no severe or serious TEAEs. Oruka plans a ~160-patient Phase 2 ORCA-SURGE psoriasis trial in 1H 2026 and a Phase 2 HS trial in 2H 2026. EVERLAST-B for ORKA-001 dosed first patients in Dec 2025 with data expected in 2027.
Oruka Therapeutics (Nasdaq: ORKA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. Oruka's presentation is scheduled for Thursday, January 15, 2026 at 9:00 AM PT. A live webcast and replay will be available on the company's investor events website.
The company is a clinical-stage biotechnology firm developing novel biologics for chronic skin diseases including plaque psoriasis. Investors can access the webcast and replay via Oruka's investor events page.
Oruka Therapeutics (Nasdaq: ORKA) announced a board transition on December 11, 2025: Chris Martin was appointed to the Board and Cameron Turtle, DPhil, resigned effective the same date.
Mr. Martin brings 25+ years of commercial experience across sales, marketing, market access, commercial operations, and business development and most recently served as Chief Commercial Officer at Verona Pharma, which was acquired by Merck in October 2025 for approximately $10B. Oruka said Martin's expertise will support late‑stage development and commercialization planning for its co‑lead programs ORKA-001 and ORKA-002.
Oruka Therapeutics (Nasdaq: ORKA) reported Q3 2025 results and a corporate update highlighting clinical progress and a strengthened balance sheet. Key clinical readouts: ORKA-001 Phase 1 interim data showed a ~100-day half-life (>3x risankizumab) and sustained STAT3 inhibition, supporting potential once-per-year dosing. ORKA-001 Phase 2a (EVERLAST-A) is enrolling with PASI 100 Week 16 data expected 2H 2026; EVERLAST-B dosing planned 1H 2026. ORKA-002 Phase 1 data expected around year-end 2025 and Phase 2 planned 1H 2026. Cash, cash equivalents, and marketable securities totaled $500.9M as of Sept 30, 2025.
Oruka Therapeutics (Nasdaq: ORKA) will present at multiple investor conferences in November 2025, providing updates on its clinical-stage biologics for chronic skin diseases including plaque psoriasis.
Scheduled presentations: Guggenheim Healthcare Innovation on Nov 10, 2025 at 9:00 AM ET; Stifel 2025 Healthcare on Nov 11, 2025 at 4:40 PM ET; and Jefferies Global Healthcare on Nov 18, 2025 at 2:00 PM GMT. A webcast and replay will be available on Oruka's investor events website.
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on chronic skin disease treatments, has secured a $180 million PIPE financing led by Viking Global Investors with participation from multiple prominent healthcare investors.
The financing includes the sale of 10.93 million common shares at $15.00 per share and 1.07 million pre-funded warrants at $14.999 each. Following the transaction, Oruka will have approximately 67.1 million shares outstanding. The deal is expected to close around September 19, 2025.
The proceeds will fund research and development, corporate expenses, and working capital, supporting operations through key clinical trial readouts including ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b in 2027.
Oruka Therapeutics (NASDAQ:ORKA) announced positive interim Phase 1 results for ORKA-001, their novel long-acting IL-23p19 antibody for plaque psoriasis treatment. The drug demonstrated an exceptional 100-day half-life, over three times longer than risankizumab, potentially enabling once-yearly dosing.
Key findings include complete STAT3 signaling inhibition through 24 weeks and a favorable safety profile with no severe adverse events. The ongoing EVERLAST-A Phase 2a trial is enrolling approximately 80 patients, with initial data expected in 2H 2026. Additionally, Oruka plans to initiate EVERLAST-B, a dose-ranging Phase 2b trial, in 1H 2026.
Oruka Therapeutics (NASDAQ: ORKA), a clinical-stage biotech company, has reported significant progress in its Q2 2025 pipeline development for chronic skin disease treatments. The company has initiated the EVERLAST-A Phase 2a trial for ORKA-001, their novel IL-23p19 antibody, with first patients dosed and data expected in 2H 2026.
Key financial metrics show a strong position with $351.5 million in cash and equivalents. R&D expenses increased to $24.1 million from $18.7 million year-over-year, while net loss widened to $24.6 million. The company is advancing multiple programs, including ORKA-002 (IL-17A/F antibody) in Phase 1 trials, with data expected around YE 2025, and the development of ORKA-021, a sequential combination therapy.
Oruka Therapeutics (NASDAQ:ORKA) announced FDA clearance of its IND application for the EVERLAST-A Phase 2a trial of ORKA-001, its long-acting anti-IL-23p19 antibody for moderate-to-severe psoriasis. The trial will enroll 80 patients in a 3:1 randomization to receive ORKA-001 or placebo.
The study's primary endpoint is PASI 100 at Week 16. At Week 28, patients achieving complete skin clearance will be randomized 2:1 to either discontinue treatment until disease recurrence or receive doses every six months. The innovative trial design aims to demonstrate potential for yearly dosing and extended treatment-free periods.
Interim Phase 1 data and detailed study design will be presented at the EADV Congress in September, with EVERLAST-A efficacy data expected in 2H 2026.
Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotech company focused on developing novel biologics for chronic skin diseases, has announced the promotion of Laura Sandler to the position of Chief Operating Officer. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience.
Prior to joining Oruka, Sandler served as SVP of Development Operations at CRISPR Therapeutics, where she played a key role in the development of exa-cel, the first approved CRISPR-based medicine. Her career includes senior positions at MedImmune, Quintiles, Novartis, and bluebird bio.
FAQ
What is the current stock price of Oruka Therapeutics (ORKA)?
What is the market cap of Oruka Therapeutics (ORKA)?
